Navigation Links
The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan
Date:11/14/2011

NEW YORK, Nov. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

http://www.reportlinker.com/p0365376/The-2011-Prostatic-Acid-Phosphatase-Testing-Market-US-Europe-Japan

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the PAP testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 242 pages and 11 tables

Table of Contents

I. Introduction

II. Worldwide Market and Technology Overview

A. Prostatic Acid Phosphatase: Clinical Significance

and Laboratory Practices

B. Instrumentation Review And

Market Needs

1. Abbott AxSYM

2. Abbott IMx

3. Anagen AN2000/AuraFlex

4. Beckman Coulter Access

5. BioChem Pharma SR1

6. bioMerieux Vidas Series

7. Biotrol Systems 7000

8. J&J Diagnostics/Amersham Amerlite

9. J&J Diagnostics Vitros ECI

10. Olympus PK Series

11. Roche Cobas Core

12. Roche Elecsys

13. Roche ES 22

14. Roche ES 33

15. Roche ES 300/300 AL

16. Siemens ACS: 180

17. Siemens ACS: Centaur

18. Siemens ELISA Processor II/III

19. Siemens Immuno 1

20. Siemens/Opus/Plus/Magnum

21. Siemens Stratus

22. Tosoh AIA Series

23. Wallac/Pharmacia Delfia

C. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

Chemiluminescence

Bioluminescence

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

3 SR, and others

4. Biochips/Microarrays

5. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

6. Microcomputers and Automation

7. Artificial Intelligence

8. Flow Cytometry

9. Biosensors

D. Competing/Complementing Technologies

1. CT

2. MRI

3. NMR

4. PET

5.Photonics Spectroscopy

E. Personal Testing

III. France: Market Size, Growth and Major Suppliers' Sales and Market Shares

IV. Germany: Test Volume and Diagnostics Sales Forecast by Market Segment

V. Italy: Test Volume and Diagnostics Sales Forecast by Market Segment

VI. Japan: Market Size, Growth and Major Suppliers' Sales and Market Shares

VII. Spain: Test Volume and Diagnostics Sales Forecast by Market Segment

VIII. U.K.: Test Volume and Diagnostics Sales Forecast by Market Segment

IX. U.S.A.: Market Size, Growth and Major Suppliers' Sales and Market Shares

X. Design Criteria for Decentralized Testing Products

XI. Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

XII. Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

XIII. Competitive Profiles

Abbott

AdnaGen

Ambrilia Biopharma

AMDL

Beckman Coulter

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CanAG Diagnostics

CeMines

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Gen-Probe

Guided Therapeutics

Hologic

Ipsogen

J&J Diagnostics

Kreatech

Kyowa Medex

Mackay Life Sciences

Matritech

Myriad Genetics

OncoLab

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac

Zila

List of Tables

Major Companies Developing or Marketing PAP Tests

France

PAP Test Volume and Diagnostics Sales by Market Segment

France

PAP Testing Market by Major Supplier

Germany

PAP Test Volume and Diagnostics Sales by Market Segment

Italy

PAP Test Volume and Diagnostics Sales by Market Segment

Japan

PAP Test Volume and Diagnostics Sales by Market Segment

Japan

PAP Testing Market by Major Supplier

Spain

PAP Test Volume and Diagnostics Sales by Market Segment

U.K.

PAP Test Volume and Diagnostics Sales by Market Segment

U.S.A.

PAP Test Volume and Diagnostics Sales by Market Segment

U.S.A.

PAP Testing Market by Major Supplier

To order this report:

:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

More  Market Research Report

Check our  Real Time Industry Data

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
2. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
3. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
4. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
5. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
6. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
7. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
8. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
11. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... 2016 Demonstrates changes in ... receptor selectivity   1 receptor ... entered clinical development as a new treatment for ...   --> 1 receptor agonist, ... clinical development as a new treatment for cognitive ...
(Date:2/9/2016)... Corporation (NASDAQ: PODD ) (Insulet or the Company), the ... OmniPod ® Insulin Management System, today announced ... Insulet,s Board of Directors. With his appointment, the Board is ... --> --> Mr. Lemoine ... a deep knowledge of accounting, financial reporting and internal controls ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, skin ... a variety of comprehensive procedures for facial enhancement. The treatments now available at ... enhancement and nasal reshaping. , As a result, patients can improve virtually ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s ... together more than 200 of the country’s top healthcare executives to share insights ... true benefit of the Forum is the provider-centric perspective, experience, expertise and strategy ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists ... their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% more ... challenge and learn more about the Goal Attainment Scale, Education Resources Inc. is ...
Breaking Medicine News(10 mins):